ABLYNX'S R&D DAY - MULTIPLE NANOBODY® PROGRAMMES IN CLINICAL AND PRE-CLINICAL DEVELOPMENT
(Thomson Reuters ONE) -
GHENT, Belgium, 26 October 2010 - Ablynx [Euronext Brussels: ABLX] will showcase
its clinical and pre-clinical portfolio during its( )R&D Day, to be held today
at its new facilities in Ghent, Belgium. Ablynx has built an impressive range of
Nanobody-based therapeutic programmes, seven of which could reach the clinical
proof-of-concept stage over the next three years.
R&D Day Highlights
· Progress with the clinical portfolio
Ablynx will provide an update on all its clinical programmes including its
anti-von Willebrand Factor programmes (ALX-0081/ALX-0681) for the orphan disease
indication thrombotic thrombocytopenic purpura (TTP) which recently entered a
Phase II study and its on-going Phase II study in patients with acute coronary
syndrome (ACS) undergoing percutaneous coronary intervention (PCI) where due to
some further delays in patient recruitment the Company now expects to report
clinical proof-of-concept data in the second half of 2011. Ablynx's third
clinical programme, an anti-RANKL Nanobody (ALX-0141) currently in Phase I in
post-menopausal women, is still on track to report final data during the first
half of 2011. Ablynx will also provide an overview of the status of ATN-103,
the anti-TNF-alpha Nanobody currently in Phase II clinical trials with its
partner Pfizer, which is still expected to generate proof-of-concept data in the
first half of 2011.
· Next into the clinic
Progress in three pre-clinical programmes, which are expected to enter
clinical trials during 2011, will also be detailed. Ablynx is on track to file
an IMPD for ALX-0061 (anti-IL-6R) before the end of 2010 with the goal of
entering into a Phase I/II study in rheumatoid arthritis patients during the
first quarter of 2011. The clinical plans for ALX-0651 (anti-CXCR4) for stem
cell mobilization and ALX-0171 (anti-RSV), which is the first Nanobody programme
to be administered via pulmonary delivery, will also be presented.
· Corporate and business update
Ablynx will also provide a corporate and business update on the Company's
progress and strategy going forward.
Ablynx's CEO and Chairman Dr Edwin Moses commented: "We are extremely pleased
with the rapid progress of our pipeline over the last year. ..
For more information, please contact Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan(at)ablynx.com
[HUG#1455145]
Complete version of the press release:
http://hugin.info/137912/R/1455145/395154.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 26.10.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 46157
Anzahl Zeichen: 0
contact information:
Town:
Ghent
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 338 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX'S R&D DAY - MULTIPLE NANOBODY® PROGRAMMES IN CLINICAL AND PRE-CLINICAL DEVELOPMENT"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
